Aim: The aim of this study is to investigate the effect of obesity on the treatment outcomes of lumbar transforaminal epidural steroid injections (TFESIs).
Material And Methods: This retrospective study included patients who underwent single-level TFESI in a pain management center between January 2021 and April 2023. Body mass index (BMI) of the patients was evaluated based on the World Health Organization guidelines. Non-obese individuals had a BMI below 25 kg/m2, those with a BMI between 25 and 30 kg/m2 were classified as overweight, and those with a BMI greater than or equal to 30 kg/m2 were deemed obese. The Numeric Rating Scale (NRS) scores for all patients before the procedure, at the first hour, and at the one-month follow-up were documented. Treatment success was defined as a 50% or more reduction in NRS score at one month of follow-up.
Results: This study enrolled a total of 162 participants, with a mean age of 49.5 ± 13.7 years and an average BMI of 27.7 ± 4.36 kg/m2. The mean pre-procedural pain score was 8.3 (range, 4 to 10). Significant reductions were observed in the mean pain scores at the first hour (0.90) and first month (3.3), compared to the pre-procedural NRS scores (p .001). Upon categorizing patients based on BMI, no significant differences were observed among the groups regarding age, gender, symptom duration, procedure level, magnetic resonance imaging (MRI) grade, pain scores, and treatment success.
Conclusion: Since the potential effects of obesity on the short-term results of lumbar TFESI have not been elucidated yet, practitioners should continue to apply lumbar TFESI in patients with high BMI values.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.5137/1019-5149.JTN.45956-23.3 | DOI Listing |
Aim: The aim of this study is to investigate the effect of obesity on the treatment outcomes of lumbar transforaminal epidural steroid injections (TFESIs).
Material And Methods: This retrospective study included patients who underwent single-level TFESI in a pain management center between January 2021 and April 2023. Body mass index (BMI) of the patients was evaluated based on the World Health Organization guidelines.
J Clin Pharmacol
January 2025
Department of Clinical Pharmacy, College of Pharmacy, University of Michigan, Ann Arbor, MI, USA.
Obesity significantly influences drug pharmacokinetics (PK), which challenges optimal dosing. This study examines the effects of diet-and-exercise-induced weight loss on key drug-metabolizing enzymes and gastric emptying in patients with obesity, who frequently require medications for comorbidities. Participants followed a structured weight management program promoting weight loss over 3-6 months and were not concomitantly on potential CYP inducers or inhibitors.
View Article and Find Full Text PDFPerit Dial Int
January 2025
Division of Nephrology, Department of Medicine, University of Texas Health San Antonio, San Antonio, TX, USA.
There is growing emphasis on increasing utilization of peritoneal dialysis (PD) in patients with end stage kidney disease (ESKD); however, use in patients with severe obesity has still been fraught for various reasons. We aim to assess the viability of PD in patients with severe obesity (BMI > 40 Kg/m). We conducted a retrospective chart review of patients admitted at the home dialysis center of an academic center between 2014 and 2020 (n = 99).
View Article and Find Full Text PDFCureus
December 2024
General Internal Medicine, Larkin Community Hospital Palm Springs Campus, Hialeah, USA.
Fournier's gangrene (FG) is a type of necrotizing fasciitis affecting the abdomen or perineum. It is a polymicrobial infection that progresses to an obliterating endarteritis, causing thrombosis and subsequent tissue necrosis, allowing pathogenic invasion of interfacial planes.Patients with Fournier's gangrene typically have underlying systemic conditions that cause vascular insufficiencies or immunosuppression.
View Article and Find Full Text PDFCureus
December 2024
Internal Medicine, Centro Hospitalar de Trás-os-Montes e Alto Douro, Vila Real, PRT.
Raynaud's phenomenon (RP) is characterized by episodic vasospasm of the small blood vessels, primarily affecting the fingers and toes. Management includes lifestyle modifications, pharmacological treatments, and in severe cases, surgical interventions. Here we report a case of an 80-year-old male patient with a history of hypertension, dyslipidemia, obesity, and atrial fibrillation who presented to the emergency department with edema, cyanosis, and intense pain in the fingers of both hands following a mild COVID-19 infection (no dyspnea or hypoxemia).
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!